Rapid-acting prandial insulin; faster onset and shorter duration than regular insulin.
Reference facts
- Also known as
- Humalog, Admelog
- Category
- Hormonal & Pituitary
- Mechanism of action
- Rapid-acting prandial insulin; faster onset and shorter duration than regular insulin.
- Targets
- Insulin receptor
- Indications under research or approved
- Diabetes — prandial insulin
- Regulatory status (reference entry)
- FDA-approved (1996)
- Half-life
- ~1 hour
- Sequence
- GIVEQCCTSICSLYQLENYCN
- Sequence notes
- Rapid-acting insulin: B-chain residues Pro28 and Lys29 swapped, reducing dimerization and accelerating absorption.
- Molecular weight (Da)
- 5808
- PDB accession
- 1LPH
- Originator / sponsor
- Eli Lilly
- First reported
- 1994
Primary References
Explore research articles about Insulin Lispro
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.